Discovers antibodies for drugmakers, and is now developing its own drug candidates.
$11.80close as of 2026-10-16
+102.1% over 1Y · 85.3 points ahead of the S&P 500
ABCLS&P 500 (SPY), rebased to ABCL's first close
“Can AbCellera advance ABCL635 toward Phase 3 while partner payments support the cost of its internal pipeline?”
Editorial note · updated 2026-10-08
The TenQ Radar
AbCellera Biologics in 36 checks
AbCellera Biologics on the TenQ Radar: value, growth, quality, health, shareholder returns and trend. The fuller the shape, the stronger the company. Behind each axis are six pass-or-fail checks from its filings, spelled out in the chapters below. Point at an axis to see them.
The business itself is the question here: 12 of 36 checks passed.
The AbCellera Biologics story
What drives AbCellera Biologics, what its price assumes and what could change the story, written from its own filings.
Clinical progress. In August 2026, AbCellera reported that ABCL635 met its Phase 2 primary efficacy endpoints for reducing the frequency and severity of hot flashes associated with menopause.
Revenue remains uneven. Revenue fell to $4.1 million in the quarter to June 2026 from $17.1 million in the prior year quarter, while net loss increased to $55.4 million from $34.7 million.
Liquidity supports development. AbCellera reported over $675 million in available liquidity at June 2026, including over $565 million in total cash balances and marketable securities and $110 million in available government funding.
Q2 '26 · quarter to 30 June 2026 · reported 5 August 2026 · Earnings release ↗
Revenue$4M-76%vs 2025-51%vs Q1
Earnings-$55M-$21Mvs 2025-$12Mvs Q1
What the release says
Highlights
AbCellera completed enrollment for the Phase 2 study of ABCL635, with top-line data expected in August 2026.
The company signed new collaborations with Jazz Pharmaceuticals and Vertex Pharmaceuticals, adding over $100 million in upfront cash to its balance sheet and eligibility for significant future milestone and royalty payments.
AbCellera ended the quarter with over $565 million in total cash balances and marketable securities, and over $675 million in total available liquidity including government funding.
At the end of Q2 2026, partners led 35 programs in which AbCellera holds a downstream stake, down from 44 at the end of 2025, and 12 molecules in the clinic understood to be progressing.
What management expects
Top-line data readout from the Phase 2 trial of ABCL635 is expected in August 2026.
Top-line data from the completed Phase 1 study of ABCL575 is expected in Q4 2026.
Key risks
New Material differences between preliminary, top-line data and final data, or a failure to replicate positive early results in subsequent, larger-scale trials, could result in clinical holds, development delays, or discontinuation of the ABCL635 program.
New Cross-study comparisons used in evaluating ABCL635 are not based on head-to-head clinical trials and may not be reliable predictors of relative efficacy or benefits compared to other product candidates, which could impact the perceived value or success of the program.
AbCellera may not be able to generate sufficient revenue to achieve profitability, as its success depends on developing and monetizing a drug either independently or through significant economic participation, and it expects to continue incurring losses for the foreseeable future.
The company's revenue is highly variable and dependent on the success and timing of milestone and royalty payments from partners, which are outside of AbCellera's control and may not be achieved as expected.
AbCellera's business model relies on the advancement and commercialization of drug candidates by its partners, over which it has no control regarding clinical development, regulatory strategy, or commercialization efforts, potentially limiting future milestone and royalty payments.
Clinical trials for AbCellera's drug candidates are subject to significant risks including delays, unforeseen safety or efficacy issues, and regulatory challenges, any of which could prevent timely completion or commercialization of its drug candidates.
AI summary of the company's filings, every number checked against them · 8 October 2026 · Sources: earnings release, 10-K, 10-Q
Earnings alerts
An email when AbCellera Biologics reports, with its results and highlights. Free with a watchlist account.
I
Value
●●●●●●0/6
Expensive against its own history and its sector (judged on sales, as it is not yet profitable): the price asks a lot of the business.
-no history
54.7xown 5-year median 21.1x
-3.3%cash earned per $ of price
-whole-business multiple
Valuation history
Is ABCL's P/E, P/S or P/B high or low against its own past?
Year
P/E
P/S
P/B
2021
51.6021
21.1061
7.7204
2022
20.1132
6.5681
2.5852
2026
-
54.6743
4.0379
◌ 2026 = at the latest close (2026-10-16), over the trailing twelve months; earlier years are annual averages · the last point is at the latest close (2026-10-16); earlier quarters use that quarter's average price over the trailing twelve months to it
→At 54.7x sales, the market is paying +159% more than ABCL's own 5-year median of 21.1x. Expectations are elevated, so more has to go right to justify the price.
What this measures
What the market has paid for each dollar of earnings, sales or book value, every year, with today's multiple as the last point and the median drawn across.
What good looks like. There is no good level. What matters is the distance from the company's own history, and whether the business has changed enough to justify it.
If it rises or falls. A multiple above its own median means the market expects more than it used to, so more has to go right. Below the median means the opposite, and the question is whether the pessimism is deserved. A multiple can also fall because earnings rose, which is the good way.
Free cash flow yield
What is ABCL's free cash flow yield at today's price?
Period
FCF yield
2021
0.0235
2022
0.0648
2023
-0.0629
2024
-0.1768
2025
-0.1629
2026
-0.0331
◌ 2026 = at the latest close (2026-10-16), over the trailing twelve months; earlier years are annual averages · the last point is at the latest close (2026-10-16); earlier quarters use that quarter's average price over the trailing twelve months to it
→Every dollar of market value currently buys -3.3% of annual free cash flow, less than its 5-year median of -6.3% - you are paying up for the same cash.
What this measures
Free cash flow divided by market value: the cash the business generates for every dollar you pay for it. The inverse of a price-to-cash multiple.
What good looks like. A yield at or above the company's own history, and one that compares well with what cash is worth elsewhere.
If it rises or falls. The yield rises when cash grows or the price falls, so a high yield is either a bargain or a warning about the cash continuing. Read it beside the cash conversion chart, which shows whether the cash is holding up.
What does “Value” actually mean?
Value asks what you pay for each dollar of earnings, sales or cash the business produces. A high multiple isn't automatically bad - fast growers earn theirs - but a price far above the company's own history means the market expects a lot to go right. We compare each multiple to the company's own past and to its sector, never to a universal rule.
not profitable: no free cash flow or earnings for the price to rest on
II
Growth
●●●●●●2/6
Growth is weak or inconsistent. The trend, not the story, is the problem.
+101.3%vs the year before
-46.3%compound annual
-net income growth
-compound annual
Revenue history
Is ABCL's revenue growing?
◌ dashed quarter = Q4 derived from the annual filing minus Q1, Q2 and Q3 (the SEC never receives a Q4 report)
Period
Revenue ($)
Q1 2020
4.7M
Q2 2020
11.2M
Q3 2020
9.4M
Q4 2020
207.9M
Q1 2021
202.7M
Q2 2021
27.6M
Q3 2021
5.5M
Q4 2021
139.3M
Q1 2022
316.6M
Q2 2022
45.9M
Q3 2022
101.4M
Q4 2022
21.5M
Q1 2023
12.2M
Q2 2023
10.1M
Q3 2023
6.6M
Q4 2023
9.2M
Q1 2024
10.0M
Q2 2024
7.3M
Q3 2024
6.5M
Q4 2024
5.0M
Q1 2025
4.2M
Q2 2025
17.1M
Q3 2025
9.0M
Q4 2025
44.9M
Q1 2026
8.3M
Q2 2026
4.0M
2019
11.6M
2020
233.2M
2021
375.2M
2022
485.4M
2023
38.0M
2024
28.8M
2025
75.1M
→Revenue reached $75M in 2025, compounding -46% a year since 2022 though the pace has cooled. The trailing twelve months are already running at $66M, behind the last full year.
What this measures
The money customers paid, before any costs are taken out. Each bar is one quarter or, on the annual view, a full financial year; the last annual bar may be the trailing twelve months, which the footnote marks.
What good looks like. Growth that repeats, rather than one strong year carrying the chart, and a trailing twelve months keeping pace with the last full year.
If it rises or falls. Revenue is the hardest line to flatter, so a rise is the most trustworthy kind of growth. A fall puts pressure on every margin below it, because costs rarely come down as quickly as sales do.
Revenue by productInsight
Where does AbCellera Biologics' revenue come from?
→Research Fees is AbCellera Biologics' larger product line at $4M, 96% of $4M in 2026Q2, against $149,000 for Licensing and Royalty Revenue.
Source: SEC filings - segment disclosures (XBRL notes) · as at 2026-06-30
Profit history
Is ABCL's net profit growing?
◌ dashed quarter = Q4 derived from the annual filing minus Q1, Q2 and Q3 (the SEC never receives a Q4 report)
Period
Net income ($)
Q1 2020
-2.1M
Q2 2020
6.7M
Q3 2020
-2.7M
Q4 2020
117.0M
Q1 2021
117.2M
Q2 2021
-2.3M
Q3 2021
-21.4M
Q4 2021
59.9M
Q1 2022
168.6M
Q2 2022
-6.8M
Q3 2022
26.6M
Q4 2022
-29.9M
Q1 2023
-40.1M
Q2 2023
-30.5M
Q3 2023
-28.6M
Q4 2023
-47.1M
Q1 2024
-40.6M
Q2 2024
-36.9M
Q3 2024
-51.1M
Q4 2024
-34.2M
Q1 2025
-45.6M
Q2 2025
-34.7M
Q3 2025
-57.1M
Q4 2025
-8.9M
Q1 2026
-43.2M
Q2 2026
-55.4M
2019
-2.2M
2020
118.9M
2021
153.5M
2022
158.5M
2023
-146.4M
2024
-162.9M
2025
-146.4M
→The company lost $146M in 2025, less than the $163M it lost the year before. The losses are narrowing, but it is still burning shareholder money.
What this measures
What is left after every cost, including tax and interest. The bottom line of the income statement.
What good looks like. Profit growing at least as fast as revenue, which means the business is keeping more of each sale as it gets bigger.
If it rises or falls. Profit can move for reasons revenue cannot explain - a one-off charge, a tax change, a write-down - so a single sharp year is worth checking against the margin chart before reading it as a trend.
Growth rate
How fast are ABCL's revenue and earnings growing?
Year
Revenue growth
Earnings growth
2,020
19.0788
-
2,021
0.6092
0.2905
2,022
0.2938
0.0329
2,023
-0.9217
-1.9235
2,024
-0.2417
-
2,025
1.6056
-
2026
1.0129
-
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · on the quarterly views, growth is the trailing twelve months against the twelve before, or a quarter against the same quarter a year earlier
→Revenue grew 101% over the twelve months to 2026-06-30, against an average of +27% a year over 2021-2025.
What this measures
How much revenue and earnings changed against the year before - the trailing twelve months against the twelve before them at each quarter, or one point per fiscal year. It is the speed of the business, not its size.
What good looks like. The earnings line above the revenue line: profits growing faster than sales means each new dollar of sales arrives more profitably than the last.
If it rises or falls. A high growth rate off a small base is easy and gets harder every year, so slowing growth in a large business is normal rather than a warning. Earnings falling while revenue grows is the combination worth understanding: costs are rising faster than sales.
Per-share growth
Are ABCL's revenue and free cash flow per share growing?
Year
Revenue per share ($)
Free cash flow per share ($)
2,019
0.0767
-0.0086
2,020
0.8861
0.0495
2,021
1.1788
0.5848
2,022
1.5419
0.6566
2,023
0.1315
-0.4178
2,024
0.098
-0.6352
2,025
0.2515
-0.5827
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→Revenue per share reached $0.25 in 2025, compounding -45% a year - in line with ABCL's own -46%, so the share count is not distorting your slice. The trailing twelve months are running at $0.22 a share. Free cash flow per share stands at $-0.58.
What this measures
Revenue and free cash flow, each divided by the number of shares in issue and adjusted for splits so old and new years compare honestly. Both lines rising means each share owns more of the business's sales and cash.
What good looks like. Both lines rising, and revenue per share growing at least as fast as the company's total revenue, which the answer compares. Faster means buybacks are working for you; slower means new shares are absorbing part of the growth.
If it rises or falls. This is the line that actually reaches you. A company can grow revenue every year and still shrink your slice by issuing shares faster than it grows.
What does “Growth” actually mean?
Growth here is what the company has actually reported to the SEC - not a forecast. We look at the last year, the three-year pace, whether growth is speeding up or slowing down, and whether it's been consistent rather than one lucky year. Hatched bars are fourth quarters we derived from annual filings (companies file a full-year 10-K rather than a Q4 report).
Profitability is thin or negative. The growth isn't turning into money yet.
-kept after direct costs
-340.2%kept after running costs
-17.3%profit on shareholders' money
-17.9%against a 10% cost of capital
-operating cash ÷ net income
Margins
What profit margin does ABCL keep on each sale?
Year
Gross
Operating
Net
2,019
-
-0.3545
-0.1904
2,020
-
0.6692
0.51
2,021
-
0.5448
0.409
2,022
-
0.446
0.3266
2,023
-
-6.2382
-3.85
2,024
-
-10.9169
-5.6483
2,025
-
-2.8898
-1.9488
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→Operating margin compressed 334 points to -289% since 2022. The bottom line is still negative: costs below the operating line eat what is left. ABCL doesn't tag a gross-profit line in its filings, so the chart starts at operating margin.
What this measures
What survives at three points on the way down the income statement: after the direct cost of the product, after the cost of running the company, and after everything.
What good looks like. Margins that hold or widen as the business grows. The level itself varies enormously by industry, so the shape over time tells you more than the number.
If it rises or falls. A widening margin means pricing power or costs under control. A compressing one means the opposite, and it compounds: on large revenue, two points of margin is a great deal of profit.
Earnings quality
Does ABCL's operating cash flow keep up with its profit?
Year
Cash from operations
Net income
2,019
2.7M
-2.2M
2,020
22.7M
118.9M
2,021
244.6M
153.5M
2,022
277.4M
158.5M
2,023
-43.9M
-146.4M
2,024
-108.6M
-162.9M
2,025
-131.3M
-146.4M
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→The company generated -$131M of operating cash in 2025. With no profit to compare against, cash generation is the number that matters here.
What this measures
Reported profit against the cash the business actually collected from operating. Profit is an accounting judgement; cash is not.
What good looks like. Cash at or above profit, year after year. Depreciation and other non-cash charges usually push cash above profit, so roughly 100% or more is healthy.
If it rises or falls. Cash falling behind profit for more than a year is the classic early warning: the sales are booked but the money has not arrived, and it shows up in receivables and inventory. For a lender the comparison behaves differently, because a growing loan book consumes cash.
Returns on capital
What return on equity and on capital does ABCL earn?
Year
ROE
ROA
ROCE
2,019
-0.2023
-
-
2,020
0.2829
0.1183
0.173
2,021
0.1653
0.1164
0.1706
2,022
0.1403
0.1029
0.1522
2,023
-0.1227
-0.0984
-0.1733
2,024
-0.1475
-0.1197
-0.2452
2,025
-0.1447
-0.1079
-0.168
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→ROE of -17% and ROCE of -18% sit close together, so the returns come from the business itself rather than from borrowing.
What this measures
Two returns side by side: on shareholders' capital (ROE), and on all the capital in the business including debt (ROCE).
What good looks like. Both comfortably above roughly 10%, and close together. A wide gap means borrowing, not operations, is doing the work.
If it rises or falls. A high ROE built on debt looks like quality until the debt has to be refinanced. ROCE is the harder number to flatter, which is why both are shown.
Cash conversion
How much of each sale does ABCL turn into free cash flow?
Period
FCF margin
2019
-0.1122
2020
0.0558
2021
0.4961
2022
0.4258
2023
-3.1775
2024
-6.484
2025
-2.3169
→Free cash flow is negative, so no share of revenue is currently converting to spare cash. Every sales dollar is being reinvested or consumed.
What this measures
Free cash flow as a share of revenue: how much of each dollar of sales survives both costs and capital spending.
What good looks like. A steady or rising share. Asset-light businesses convert far more than manufacturers, so compare a company with itself.
If it rises or falls. Falling conversion while revenue grows means growth is being bought with capital spending or working capital, which is fine while it lasts and painful when it stops.
Spending intensity
How much of its revenue does ABCL spend on capex, R&D and stock pay?
Year
Capex % of rev
R&D % of rev
Stock comp % of rev
2,019
0.3442
0.8709
0.0766
2,020
0.0415
0.1261
0.036
2,021
0.1558
0.1654
0.0817
2,022
0.1456
0.2222
0.1019
2,023
2.0236
4.6195
1.6879
2,024
2.719
5.801
2.3439
2,025
0.5693
2.4868
0.7426
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→The biggest claim on each sales dollar is research and development, at 249% of revenue (stock compensation 74%, capital spending 57%). That share has risen since 2022, so the cost of competing is climbing.
What this measures
Capital spending, research and development, and stock compensation, each as a share of revenue. The three ways a business pays to keep its position.
What good looks like. A share that is stable or falling while revenue grows, which means the cost of competing is not rising with the business.
If it rises or falls. Rising intensity means each new dollar of sales is getting more expensive to win. Falling intensity can mean efficiency, or it can mean under-investment that shows up years later.
Return on capital employed
Is ABCL's return on capital above what its capital costs?
Period
Return on capital employed
2020
0.173
2021
0.1706
2022
0.1522
2023
-0.1733
2024
-0.2452
2025
-0.168
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→ABCL's return on capital is negative at -16.8% in 2025. The capital in the business is not yet earning anything back.
What this measures
The same return as the card above, but every filed year, against a 10% line that stands in for what capital costs.
What good looks like. Years above the line, and a trend that is flat or rising rather than drifting down towards it.
If it rises or falls. A business earning above its cost of capital creates value by growing; one earning below it destroys value by growing. The 10% line is a convention, not a law, so read the distance from it rather than the crossing.
What does “Quality” actually mean?
Quality asks whether the growth makes real money. Margins show how much of each sale survives costs; return on equity shows what shareholders earn on their capital; and the profit-to-cash comparison catches companies whose accounting profits never turn into actual cash.
TTM operating cash flow -$95M on a net loss of $165M
IV
Financial health
●●●●●●4/6
Financially sound overall, with one or two things worth watching.
0.00xborrowed vs owned
12.8xnear-term bills coverage
-earnings ÷ interest bill
$120Mcash plus short-term investments
Debt & cash
How much debt does ABCL carry, and do its profits cover the interest?
Year
Total debt
Cash & investments
2,018
-
-
2,019
-
-
2,020
190,000
594.1M
2,021
190,000
476.1M
2,022
0
386.5M
2,023
0
133.3M
2,024
-
156.3M
2,025
0
128.5M
2,026
0
120.1M
◌ each quarterly point is the balance sheet at that quarter end
→The company holds $120M in cash against $0.00 of debt - a net-cash balance sheet, which means a bad year is an inconvenience rather than a threat.
What this measures
Total borrowings against cash on hand, with debt as a multiple of shareholders' equity, and how many times profit covers the interest bill.
What good looks like. Interest covered comfortably - roughly eight times or more - and debt that is not a large multiple of equity.
If it rises or falls. Debt is only a problem when it has to be repaid or refinanced in a bad year, so cover matters more than the amount. Rising debt with rising cover is a business borrowing to grow; rising debt with falling cover is the combination that ends badly.
Near-term liquidity
Do ABCL's current assets cover the bills due within a year?
Period
Current ratio
2020
7.859
2021
7.7049
2022
8.6671
2023
7.3268
2024
9.8075
2025
11.3243
◌ 2026 = the latest balance sheet (2026-06-30), not a fiscal year-end · each quarterly point is the balance sheet at that quarter end
→Near-term liquidity is comfortable: 12.8x of current assets for every dollar due within the year. That is stronger than in 2020.
What this measures
Current assets over current liabilities: what the company can turn into cash within a year against what it owes within a year.
What good looks like. Comfortably above 1.0, and not falling year after year. Below 1.0 means near-term bills exceed near-term resources, which is normal for some business models and a warning in others.
If it rises or falls. Inventory and receivables build it up; short-term borrowing and payables pull it down. A retailer that turns stock over quickly can run lower than a manufacturer and be perfectly sound.
Cash conversion
How much of ABCL's revenue arrives as operating cash?
Period
Operating cash flow / revenue
2019
0.232
2020
0.0973
2021
0.6519
2022
0.5714
2023
-1.1539
2024
-3.765
2025
-1.7476
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→ABCL's operations consumed cash rather than produced it over the last twelve months. Down from 23.2% in 2019.
What this measures
Operating cash flow as a share of revenue: of every dollar sold, how much reached the bank before capital spending.
What good looks like. A high share, holding up or improving. It is the clearest sign that reported profit is real.
If it rises or falls. It falls when customers take longer to pay or stock builds up, and it can stay high while profit falls - which is usually the more reassuring of the two.
Shareholders' equity
Is ABCL's shareholder equity (book value) growing?
Period
Equity ($)
2018
11.6M
2019
10.3M
2020
830.5M
2021
1.03B
2022
1.23B
2023
1.15B
2024
1.06B
2025
966.9M
2026
896.0M
→The company's own capital shrank from $1.2B in 2023 to $896M (-22%). Buybacks or losses are drawing the buffer down - the distinction matters.
What this measures
What would be left for shareholders if every asset were sold at its book value and every debt repaid. Book value, in other words.
What good looks like. Equity growing as retained profits build up, unless the company is deliberately returning more than it earns.
If it rises or falls. Equity falls for two very different reasons: buybacks, which return money to you, and losses, which do not. The distinction is the whole story, and negative equity means liabilities now exceed assets, which makes debt-to-equity and return on equity meaningless rather than alarming.
What does “Health” actually mean?
Health asks one question: can the business survive a bad year? We check whether near-term bills are covered, whether debt is modest and shrinking, whether earnings comfortably pay the interest, and - for loss-makers - how many years of cash are left at the current burn rate.
ABCL returns nothing to shareholders yet. Every dollar stays in the business.
-bought back, TTM, over market value
-at the current rate
-dividends plus buybacks
$51Mlast 12m, dilutes the buybacks
+99.2%since 2019 (split-adjusted)
Share count change (split-adjusted)
Is ABCL's share count rising or falling?
Year
Share-count change
2,020
0.7388
2,021
0.2096
2,022
-0.0109
2,023
-0.0815
2,024
0.0178
2,025
0.0149
→The share count grew 1.5% in 2025. Your slice of the company shrinks by that much each year unless earnings grow faster.
What this measures
The yearly change in the number of shares in issue, adjusted for splits so the years compare. A bar below zero is a falling share count, usually from buybacks; above zero, new shares were issued.
What good looks like. A flat or falling share count. Falling means each share you hold owns a little more of the business every year.
If it rises or falls. A rising count divides the same business among more owners, so your slice shrinks unless profits grow faster. This is the most direct chart on the page: it is your ownership, measured.
Dilution against what it bought
Has ABCL's revenue per share grown faster than its share count?
Change since 2019. The gap between the lines is what each share gained or lost. Share counts are split-adjusted weighted averages.
Year
Share count, change since 2019
Revenue per share, change since 2019
2,019
0
0
2,020
0.7388
10.5474
2,021
1.1033
14.362
2,022
1.0804
19.0937
2,023
0.9109
0.7137
2,024
0.945
0.2766
2,025
0.9739
2.2777
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · on the quarterly view, revenue per share is the trailing twelve months over that quarter's diluted count
→ABCL issued 97% more shares from 2019 to 2025, but revenue per share still rose 228%. The dilution bought more growth than it cost existing holders.
What this measures
The share count and revenue per share over the same years, both indexed to 100 at the start, so the two lines can be compared directly.
What good looks like. The per-share line above the share-count line: whatever the company did with its shares, more business ended up behind each one.
If it rises or falls. Issuing shares is not automatically bad. It is bad when the money raised buys less growth than the dilution cost, which is exactly what the gap between these two lines shows.
Why compare buybacks with stock compensation?
A company can trumpet billions in buybacks while quietly issuing nearly as much stock to employees. What matters to you is the net effect: is the share count actually falling? If not, the 'return' is mostly recycling.
→ABCL is in a clear uptrend: the price is above the cloud where recent trading settled, and that cloud is still rising underneath it. The last two weeks and the month-ago comparison both point up, so the shorter readings back the trend.
How the trend above is worked out
The trend read is the daily Ichimoku picture, the same indicator drawn on the chart above. Five names, and what each one is: the TENKAN is the midpoint of the last 9 sessions' high and low, the fast line; the KIJUN is the same over 26 sessions, the slow one; the two SENKOU spans are midpoints drawn 26 sessions into the FUTURE, and the band between them is the KUMO cloud - because it is drawn forward, the support for the coming weeks is already fixed and a change of its direction can be seen coming; the CHIKOU is today's close compared with the close 26 sessions back. A trend confirms itself in that order and the checks follow it: price clears the cloud, holds above both lines, the Tenkan crosses above the Kijun, the cloud ahead turns up, and the Chikou stands higher than the price a month ago. Six of six therefore means all of that at once; a price sitting inside the cloud, or below its own lines, cannot get there. The last check is the one Ichimoku cannot answer - whether the S&P 500 did better over 12 months (252 sessions), measured on the SPY ETF with dividends included, on the same adjusted basis as the stock's own price. Our figures are the last close we hold, refreshed every trading night; the chart is live. None of this says anything about the business, and it is not advice.
Are ABCL's insiders buying or selling shares with their own money?
Month
Buys ($)
Sells ($)
2023-11
137,400
0
2023-12
0
0
2024-01
0
0
2024-02
0
0
2024-03
0
0
2024-04
0
0
2024-05
0
0
2024-06
0
0
2024-07
0
0
2024-08
739,977
0
2024-09
0
0
2024-10
0
0
2024-11
0
0
2024-12
0
0
2025-01
0
0
2025-02
0
0
2025-03
940,311
0
2025-04
0
0
2025-05
0
0
2025-06
0
0
2025-07
0
0
2025-08
0
0
2025-09
0
0
2025-10
0
0
2025-11
178,460
0
2025-12
0
0
2026-01
0
0
2026-02
856,696
0
2026-03
0
0
2026-04
0
0
2026-05
95,400
0
2026-06
0
0
2026-07
0
0
2026-08
1.5M
0
2026-09
0
0
2026-10
0
0
→Since November 2023, insiders bought $4M of stock on the open market and sold nothing. Buying with their own money is the one insider signal that is hard to explain away. A further 11 transactions were grants, option exercises or tax withholding, which say nothing either way.
What this measures
Open-market buys and sells by the company's own officers and directors, from their Form 4 filings. Grants, option exercises and shares withheld for tax are excluded, because they are compensation rather than decisions.
What good looks like. Buying with their own money, which is the one insider action that is hard to explain away.
If it rises or falls. Selling is weak evidence: insiders sell to diversify, to buy houses, and on pre-scheduled plans set months ahead. Buying is stronger evidence, because there is only one reason to do it. The absence of any buying over a long stretch is itself worth noticing.
The record
Who did what, exactly?
Date
Insider
Role
Type
Shares
Price
Value
2026-08-24
Michael R Hayden
Director
BUY
53,613
$10.64
$570,442
2026-08-18
John S. Montalbano
Director
BUY
10,000
$11.03
$110,300
2026-08-14
Andrew Booth
Chief Financial Officer
BUY
37,200
$10.32
$383,904
2026-08-12
Michael R Hayden
Director
BUY
46,387
$10.37
$481,033
2026-06-03
Andrew Booth
Chief Financial Officer
exercise
250,000
$0.19
$47,500
2026-05-14
John S. Montalbano
Director
BUY
20,000
$4.77
$95,400
2026-02-27
Thermopylae Holdings Ltd.
10% owner
BUY
38,000
$3.44
$130,720
2026-02-27
Andrew Booth
Chief Financial Officer
BUY
42,600
$3.42
$145,692
2026-02-26
Thermopylae Holdings Ltd.
10% owner
BUY
177,457
$3.27
$580,284
2025-11-26
John S. Montalbano
Director
BUY
50,000
$3.57
$178,460
2025-03-11
Thermopylae Holdings Ltd.
10% owner
BUY
343,631
$2.16
$742,243
2025-03-10
John S. Montalbano
Director
BUY
25,000
$2.30
$57,500
2025-03-06
John S. Montalbano
Director
BUY
60,000
$2.34
$140,568
2024-11-25
Carl L. G. Hansen
Chief Executive Officer
exercise
56,125
$2.70
$151,538
2024-09-20
Carl L. G. Hansen
Chief Executive Officer
exercise
56,125
$2.70
$151,538
2024-08-29
Thermopylae Holdings Ltd.
10% owner
BUY
283,516
$2.61
$739,977
2024-06-21
Veronique Lecault
Chief Operating Officer
exercise
83,334
$0.19
$15,667
2024-05-31
Carl L. G. Hansen
Chief Executive Officer
exercise
56,125
$2.70
$151,538
2024-02-26
Carl L. G. Hansen
Chief Executive Officer
exercise
56,125
$2.70
$151,538
2023-11-23
Carl L. G. Hansen
Chief Executive Officer
exercise
56,125
$2.70
$151,538
2023-11-08
John S. Montalbano
Director
BUY
10,000
$4.46
$44,600
2023-11-06
John S. Montalbano
Director
BUY
20,000
$4.64
$92,800
Why do the transaction types matter so much?
Most insider filings are not trades: stock grants, option exercises and tax withholding are how executives get paid, and gifts are estate planning. The signal lives in open-market transactions - a buy means an insider chose to spend their own cash on the stock. Sells are murkier: many are pre-scheduled 10b5-1 plans set months in advance. That's why the chart counts only open-market activity, and the table labels every row.
VIII
Ownership
informational
37.9%on Form 13F, 30 June 2026
38.5%officers, directors, founders
67.6%together
Top holders
Who owns AbCellera Biologics stock?
Fund managers filing Form 13F held 37.9% of the company's shares on 30 June 2026. The largest holder is Carl L. G. Hansen, with 18.6%. Insiders hold 38.5%.
#
Holder
Stake
Shares
Value
Change
1
Carl L. G. HansenChief Executive Officer · Form 4, 25 November 2024
18.59%
57.0M
$672M
-
2
Thermopylae Holdings Ltd.10% owner · Form 4, 27 February 2026
18.31%
56.1M
$662M
-
3
Baker Bros. Advisors LPFund manager
10.77%
33.0M
$390M
+9.0%
4
Capital World InvestorsFund manager
4.43%
13.6M
$160M
+1.7%
5
BAILLIE GIFFORD & COHolds over 5% · Form 13G, 30 September 2024
4.21%
12.9M
$152M
-
6
Two Sigma Investments, LPFund manager
3.40%
10.4M
$123M
-1.2%
7
TD Waterhouse Canada Inc.Fund manager
3.12%
9.6M
$113M
+0.0%
8
Bank of America CorpFund manager
2.00%
6.1M
$72M
+104.7%
9
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCFund manager
1.41%
4.3M
$51M
-43.0%
10
ArrowMark Colorado Holdings LLCFund manager
1.34%
4.1M
$48M
+0.0%
11
BlackRock, Inc.Fund manager
1.24%
3.8M
$45M
-5.8%
12
Driehaus Capital Management LLCFund manager
0.93%
2.9M
$34M
-28.8%
13
Veronique LecaultChief Operating Officer · Form 4, 21 June 2024
0.80%
2.5M
$29M
-
14
Tudor Investment Corp Et AlFund manager
0.67%
2.1M
$24M
-9.3%
15
Marshall Wace, LLPFund manager
0.62%
1.9M
$22M
+428.9%
16
UBS Group AGFund manager
0.61%
1.9M
$22M
-55.6%
17
Morgan StanleyFund manager
0.54%
1.7M
$20M
-25.0%
18
Price T Rowe Associates IncFund manager
0.52%
1.6M
$19M
New
19
Citadel Advisors LLCFund manager
0.52%
1.6M
$19M
+16.6%
20
Michael R HaydenDirector · Form 4, 24 August 2026
0.49%
1.5M
$18M
-
The full list of top holders is free with an account
Source: SEC Form 13F filings for the quarter to 30 June 2026, Schedules 13D and 13G, and Form 4. Shares on today's basis, value at the latest price.
Where does this list come from?
Fund managers with more than $100 million in US stocks report their holdings every quarter on Form 13F, up to 45 days after the quarter ends, so the fund figures are as of the last quarter end. A fund family reports as one manager, and funds together can report more than 100%: shares lent to short sellers are bought again by other funds, and both report them. Anyone holding more than 5% of a class files a Schedule 13D or 13G, and officers and directors report what they hold on Form 4 after every trade, so those rows carry their own dates. Short positions are not reported anywhere. A stake is the holder's shares as a share of all the company's shares, with other share classes converted at their market value.